Each month, the not-for-profit French journal Prescrire publishes systematic, independent analyses of the available evidence regarding new drugs, newly authorised indications for drugs already on the market, and new forms or new dose strengths of existing drugs.

The goal is to determine which of the multitude of new products or indications are useful additional treatment options, which should be used in place of other drugs, and which are to be avoided.

The annual Prescrire Awards recognise drugs, drug packaging and drug information singled out for attention by Prescrire's editorial staff. The Prescrire Awards for 2022 were announced in Paris on 1st February 2023.

 "Pilule d'Or" 

The "Pilule d'Or" ("Golden Pill") is awarded drugs that represent a major therapeutic advance in a particularly poorly served field.

• No drugs examined in 2022 were a major therapeutic advance
  

Honours List

Drugs included on the Honours List constitute a clear advance for some patients compared with existing therapeutic options, albeit with limitations.

• PAXLOVID° (nirmatrelvir + ritonavir) - Pfizer
   

Noteworthy

Drugs deemed "Noteworthy" provide a modest improvement in patient care.

• ONUREG° (azacitidine) - Bristol-Myers Squibb

For details, see:

> The Prescrire Awards for 2022
 

©Prescrire 1 March 2023

Source: "The Prescrire Awards" Prescrire International 2023; 32 (246): 80-81. Free.

Download the full article